Generic Drug

Bestselling in Generic Drug

Skip carousel

carousel previous carousel next

Ucb et. al. v. Corepharma
Author PriorSmart
Bottle of Lies: The Inside Story of the Generic Drug Boom
Author Katherine Eban
Generic Alternatives to Prescription Drugs: Your Guide to Buying Effective Drugs at Cost-Saving Prices
Author Diane Nitzki-George
Unimed Pharmaceuticals et. al. v. Perrigo Company et. al.
Author PriorSmart
Dow Pharmaceutical Sciences et. al. v. Actavis et. al.
Author PriorSmart
FDA Is Not the Problem: Why Undermining the Drug Approval Process Is Not the Answer to High Drug Prices
Author Center for American Progress
Janssen Products et. al. v. Lupin et. al.
Author PriorSmart
Generic Challenge:: Understanding Patents, FDA and Pharmaceutical Life-Cycle Management (Fifth Edition)
Author Martin a. Voet
Ferring v. Mylan et. al.
Author PriorSmart
Oral Drug Delivery Technology
Author Aukunuru Jithan
Bill Ackman Allergan Presentation
Author CanadianValue
Novartis Pharmaceuticals v. Torrent Pharmaceuticals et. al.
Author PriorSmart
NSAIDs (Nonsteroidal Anti-Inflammatory Drugs): An Overview
Author Swarnlata Saraf
Generic Drugs: A Consumer’S Self-Defense Guide
Author Clifford L. Nilsen
Forest Laboratories et. al. v. Torrent Pharmaceuticals et. al.
Author PriorSmart
SENATE HEARING, 110TH CONGRESS - FINANCIAL SERVICES AND GENERAL GOVERNMENT APPROPRIATIONS FOR FISCAL YEAR 2009
Author Scribd Government Docs
Alza v. Mylan Pharmaceuticals et. al.
Author PriorSmart
09-24-15 Edition
Author San Mateo Daily Journal
Price Watch Trends in Retail Prices of Specialty Prescription Drugs 2006 to 2013 Nov
Author Zerohedge
CEI Planet - May-June 2011
Author Competitive Enterprise Institute
Helsinn Healthcare et. al. v. Dr. Reddy's Laboratories et. al.
Author PriorSmart
AstraZeneca AB v. Mylan Pharmaceuticals
Author PriorSmart
SENATE HEARING, 109TH CONGRESS - INCREASING GENERIC DRUG USE: SAVINGS FOR SENIORS AND MEDICARE
Author Scribd Government Docs
Recordati Rare Diseases v. Exela Pharma Sciences et. al.
Author PriorSmart
Patent Monopolies and the Costs of Mismarketing Drugs
Author Center for Economic and Policy Research
Novartis Pharmaceuticals et. al. v. Mylan et. al.
Author PriorSmart
HOUSE HEARING, 110TH CONGRESS - ASSESSING THE IMPACT OF A SAFE AND EQUITABLE BIOSIMILAR POLICY IN THE UNITED STATES
Author Scribd Government Docs
05-08-15 edition
Author San Mateo Daily Journal
Dare to Lead: Public health and company wealth
Author Oxfam
Cadence Pharmaceuticals et. al. v. Paddock Laboratories et. al.
Author PriorSmart

Everything About Generic Drug

Skip carousel

carousel previous carousel next

Recently Added

Skip carousel

carousel previous carousel next

View All In Generic Drug

Language

Welcome to Scribd!

Generic Drug

Bestselling in Generic Drug

Ucb et. al. v. Corepharma

Bottle of Lies: The Inside Story of the Generic Drug Boom

Generic Alternatives to Prescription Drugs: Your Guide to Buying Effective Drugs at Cost-Saving Prices

Unimed Pharmaceuticals et. al. v. Perrigo Company et. al.

Dow Pharmaceutical Sciences et. al. v. Actavis et. al.

FDA Is Not the Problem: Why Undermining the Drug Approval Process Is Not the Answer to High Drug Prices

Janssen Products et. al. v. Lupin et. al.

Generic Challenge:: Understanding Patents, FDA and Pharmaceutical Life-Cycle Management (Fifth Edition)

Ferring v. Mylan et. al.

Oral Drug Delivery Technology

Bill Ackman Allergan Presentation

Novartis Pharmaceuticals v. Torrent Pharmaceuticals et. al.

NSAIDs (Nonsteroidal Anti-Inflammatory Drugs): An Overview

Generic Drugs: A Consumer’S Self-Defense Guide

Forest Laboratories et. al. v. Torrent Pharmaceuticals et. al.

SENATE HEARING, 110TH CONGRESS - FINANCIAL SERVICES AND GENERAL GOVERNMENT APPROPRIATIONS FOR FISCAL YEAR 2009

Alza v. Mylan Pharmaceuticals et. al.

09-24-15 Edition

Price Watch Trends in Retail Prices of Specialty Prescription Drugs 2006 to 2013 Nov

CEI Planet - May-June 2011

Helsinn Healthcare et. al. v. Dr. Reddy's Laboratories et. al.

AstraZeneca AB v. Mylan Pharmaceuticals

SENATE HEARING, 109TH CONGRESS - INCREASING GENERIC DRUG USE: SAVINGS FOR SENIORS AND MEDICARE

Recordati Rare Diseases v. Exela Pharma Sciences et. al.

Patent Monopolies and the Costs of Mismarketing Drugs

Novartis Pharmaceuticals et. al. v. Mylan et. al.

HOUSE HEARING, 110TH CONGRESS - ASSESSING THE IMPACT OF A SAFE AND EQUITABLE BIOSIMILAR POLICY IN THE UNITED STATES

05-08-15 edition

Dare to Lead: Public health and company wealth

Cadence Pharmaceuticals et. al. v. Paddock Laboratories et. al.

Everything About Generic Drug

Senate Aging Report Sudden Price Spikes in Off Patent Prescription Drugs

Janssen Products et. al. v. Lupin et. al.

HOUSE HEARING, 109TH CONGRESS - INCREASING GENERIC DRUG UTILIZATION: SAVING MONEY FOR PATIENTS

SENATE HEARING, 110TH CONGRESS - POLICY IMPLICATIONS OF PHARMACEUTICAL IMPORTATION FOR U.S. CONSUMERS

Generic Challenge:: Understanding Patents, FDA and Pharmaceutical Life-Cycle Management (Fifth Edition)

Oral Drug Delivery Technology

Bill Ackman Allergan Presentation

Generic drug maker Complaint Final (Redacted Public Version) 12 15 16

Demonizing Drugmakers: The Political Assault on the Pharmaceutical Industry, Cato Policy Analysis No. 475

NSAIDs (Nonsteroidal Anti-Inflammatory Drugs): An Overview

Generic Drugs: A Consumer’S Self-Defense Guide

Fatal Side Effects: Medicine patents under the microscope

HOUSE HEARING, 112TH CONGRESS - REVIEW OF THE PROPOSED GENERIC DRUG AND BIOSIMILARS USER FEES AND FURTHER EXAMINATION OF DRUG SHORTAGES

Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines

FDA Is Not the Problem: Why Undermining the Drug Approval Process Is Not the Answer to High Drug Prices

SENATE HEARING, 108TH CONGRESS - LEGISLATIVE AND REGULATORY RESPONSES TO THE FTC STUDY ON BARRIERS TO ENTRY IN THE PHARMACEUTICAL MARKETPLACE

09-24-15 Edition

Fatal Side Effects: Medicine patents under the microscope

Patent Injustice: How world trade rules threaten the health of poor people

05-08-15 edition

Patent Injustice: How world trade rules threaten the health of poor people

Senju Pharmaceutical et. al. v. Metrics et. al.

Dare to Lead: Public health and company wealth

Dare to Lead: Public health and company wealth

Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines

Patent Injustice: How world trade rules threaten the health of poor people

Abbott Laboratories et. al. v. Watson Pharmaceuticals et. al.

Cutting the Cost of Global Health

Otsuka Pharmaceutical v. Hetero et. al.

Niaspan Lawsuit Complaint

Recently Added

Oral Drug Delivery Technology

NSAIDs (Nonsteroidal Anti-Inflammatory Drugs): An Overview

Generic Drugs: A Consumer’S Self-Defense Guide

Bill Ackman Allergan Presentation

SENATE HEARING, 107TH CONGRESS - CLOSING THE GAPS IN HATCH-WAXMAN: ASSURING GREATER ACCESS TO AFFORDABLE PHARMACEUTICALS

SENATE HEARING, 108TH CONGRESS - EXAMINING THE SENATE AND HOUSE VERSIONS OF THE ``GREATER ACCESS TO AFFORDABLE PHARMACEUTICALS ACT''

Trading Away Access to Medicines - Revisited: How the European trade agenda continues to undermine access to medicines

Eye on the Ball: Medicine regulation - not IP enforcement - can best deliver quality medicine

US Bullying on Drug Patents: One year after Doha

Undermining Access to Medicines: Comparison of five US FTAs: A technical note

TRIPS and Public Health: The next battle

Investing For Life: Meeting poor people's needs for access to medicines through responsible business practices

Song of the Sirens: Why the US–Andean FTAs undermine sustainable development and regional integration

Robbing the Poor to Pay the Rich? How the United States keeps medicines from the world’s poorest